Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus

Authors: Peter P Toth, Robert J Simko, Swetha Rao Palli, Dawn Koselleck, Ralph A Quimbo, Mark J Cziraky

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

Few large-scale, real-world studies have assessed the relative associations of lipid fractions with diabetic microvascular events. The main objective of this study was to evaluate the association of the lipid profile components, high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), triglycerides (TG), and non-high density lipoprotein cholesterol (non-HDL-C) with microvascular complications (MVCs) in type 2 diabetes mellitus (T2DM) patients.

Methods

This observational cohort study queried the HealthCore Integrated Research Database (HIRDSM) for newly-diagnosed (Index Date) 18-64-year-old patients with diabetes mellitus between 01/01/2005-06/30/2010. Inclusion required ≥12 months pre-index continuous health plan eligibility and ≥1 pre-index lipid profile result. Patients with polycystic ovary syndrome and prior MVCs were excluded. Incident complications were defined as the earliest occurrence of diabetic retinopathy, peripheral neuropathy, and/or nephropathy post-index. Cox proportional models and Kaplan-Meier (KM) curves were used to evaluate associations among variables.

Results

Of the patients (N = 72,267), 50.05 % achieved HDL-C, 64.28 % LDL-C, 59.82 % TG, and 56.79 % non-HDL-C American Diabetes Association goals at baseline. During follow-up (mean, 21.74 months), there were 5.21 microvascular events per 1,000 patient-months. A 1-mg/dL increase in HDL-C was associated with 1 % decrease in any MVC risk (P < .0001), but for LDL-C, TG, and non-HDL-C, 1-mg/dL increase resulted in increases of 0.2 % (P < .0001), 0.1 % (P < 0.001) and 0.3 % (P < 0.001) in MVC risk. Patients achieving HDL-C goals had a 11 % lower risk of MVC versus non-achievers (RR 0.895, [95 % CI, 0.852-0.941], P < .0001). Similarly, TG goal attainment was associated with a lowered risk for any MVC (RR 0.849, [95 % CI, 0.808-0.892], P < .0001). Evaluation of KM survival curves demonstrated no significant difference in the risk of MVCs between patients achieving vs. not achieving LDL-C goals, but did demonstrate a difference in MVC risk between patients achieving vs. not achieving non-HDL-C goals.

Conclusion

This study demonstrates significant independent associations among lipid fractions and risk for microangiopathy. These findings suggest that attaining established ADA goals for HDL-C, TG, and non-HDL-C may reduce risk for microvascular events among patients with diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buse JB, Ginsberg HN, Bakris GL, et al: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007, 115: 114-126.CrossRefPubMed Buse JB, Ginsberg HN, Bakris GL, et al: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007, 115: 114-126.CrossRefPubMed
2.
go back to reference Fioretto P, Dodson PM, Ziegler D, Rosenson RS: Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010, 6: 19-25. 10.1038/nrendo.2009.213.CrossRefPubMed Fioretto P, Dodson PM, Ziegler D, Rosenson RS: Residual microvascular risk in diabetes: unmet needs and future directions. Nat Rev Endocrinol. 2010, 6: 19-25. 10.1038/nrendo.2009.213.CrossRefPubMed
3.
go back to reference Misra A, Kumar S, Kishore VN, Kumar A: The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs. 2003, 3: 325-338. 10.2165/00129784-200303050-00004.CrossRefPubMed Misra A, Kumar S, Kishore VN, Kumar A: The role of lipids in the development of diabetic microvascular complications: implications for therapy. Am J Cardiovasc Drugs. 2003, 3: 325-338. 10.2165/00129784-200303050-00004.CrossRefPubMed
5.
go back to reference Rein DB, Zhang P, Wirth KE, et al: The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006, 124: 1754-1760. 10.1001/archopht.124.12.1754.CrossRefPubMed Rein DB, Zhang P, Wirth KE, et al: The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006, 124: 1754-1760. 10.1001/archopht.124.12.1754.CrossRefPubMed
6.
go back to reference Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications. 2004, 18: 18-26. 10.1016/S1056-8727(03)00035-7.CrossRefPubMed Gordois A, Scuffham P, Shearer A, Oglesby A: The health care costs of diabetic nephropathy in the United States and the United Kingdom. J Diabetes Complications. 2004, 18: 18-26. 10.1016/S1056-8727(03)00035-7.CrossRefPubMed
7.
go back to reference Leiter LA: The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Pract. 2005, 68 (Suppl 2): S3-14.CrossRefPubMed Leiter LA: The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Pract. 2005, 68 (Suppl 2): S3-14.CrossRefPubMed
8.
go back to reference Harris SB, Naqshbandi M, Bhattacharyya O, et al: Major gaps in diabetes clinical care among Canada's First Nations: results of the CIRCLE study. Diab Res Clin Pract. 2011, 92: 272-279. 10.1016/j.diabres.2011.02.006.CrossRef Harris SB, Naqshbandi M, Bhattacharyya O, et al: Major gaps in diabetes clinical care among Canada's First Nations: results of the CIRCLE study. Diab Res Clin Pract. 2011, 92: 272-279. 10.1016/j.diabres.2011.02.006.CrossRef
9.
go back to reference Larsson LI, Alm A, Lithner F, Dahlen G, Bergstrom R: The association of hyperlipidemia with retinopathy in diabetic patients aged 15–50 years in the county of Umea. Acta Ophthalmol Scand. 1999, 77: 585-591. 10.1034/j.1600-0420.1999.770522.x.CrossRefPubMed Larsson LI, Alm A, Lithner F, Dahlen G, Bergstrom R: The association of hyperlipidemia with retinopathy in diabetic patients aged 15–50 years in the county of Umea. Acta Ophthalmol Scand. 1999, 77: 585-591. 10.1034/j.1600-0420.1999.770522.x.CrossRefPubMed
10.
go back to reference Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy?. Am J Kidney Dis. 1993, 22: 196-201.CrossRefPubMed Mulec H, Johnsen SA, Wiklund O, Bjorck S: Cholesterol: a renal risk factor in diabetic nephropathy?. Am J Kidney Dis. 1993, 22: 196-201.CrossRefPubMed
11.
go back to reference Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ: Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes. 1997, 46: 665-670. 10.2337/diabetes.46.4.665.CrossRefPubMed Forrest KY, Maser RE, Pambianco G, Becker DJ, Orchard TJ: Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes. 1997, 46: 665-670. 10.2337/diabetes.46.4.665.CrossRefPubMed
12.
go back to reference Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S11-S61. Standards of medical care in diabetes--2010. Diabetes Care. 2010, 33 (Suppl 1): S11-S61.
13.
go back to reference National Cholesterol Education Program: Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication No. 02–5215. 2002, MD: National Heart Lung and Blood Institute, Bethesda National Cholesterol Education Program: Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication No. 02–5215. 2002, MD: National Heart Lung and Blood Institute, Bethesda
14.
go back to reference Mosca L, Banka CL, Benjamin EJ, et al: Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007, 115: 1481-1501. 10.1161/CIRCULATIONAHA.107.181546.CrossRefPubMed Mosca L, Banka CL, Benjamin EJ, et al: Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007, 115: 1481-1501. 10.1161/CIRCULATIONAHA.107.181546.CrossRefPubMed
15.
go back to reference Leslie RS: Using arrays to calculate medication utilization. 2007, SAS Global Forum Leslie RS: Using arrays to calculate medication utilization. 2007, SAS Global Forum
16.
go back to reference Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M: A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007, 10: 3-12. 10.1111/j.1524-4733.2006.00139.x.CrossRefPubMed Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M: A checklist for medication compliance and persistence studies using retrospective databases. Value Health. 2007, 10: 3-12. 10.1111/j.1524-4733.2006.00139.x.CrossRefPubMed
17.
go back to reference Costa J, Borges M, David C, Vaz CA: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Br Med J. 2006, 332: 1115-1124. 10.1136/bmj.38793.468449.AE.CrossRef Costa J, Borges M, David C, Vaz CA: Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. Br Med J. 2006, 332: 1115-1124. 10.1136/bmj.38793.468449.AE.CrossRef
18.
go back to reference Kordonouri O, Danne T, Hopfenmuller W, Enders I, Hovener G, Weber B: Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus?. Acta Paediatr. 1996, 85: 43-48. 10.1111/j.1651-2227.1996.tb13888.x.CrossRefPubMed Kordonouri O, Danne T, Hopfenmuller W, Enders I, Hovener G, Weber B: Lipid profiles and blood pressure: are they risk factors for the development of early background retinopathy and incipient nephropathy in children with insulin-dependent diabetes mellitus?. Acta Paediatr. 1996, 85: 43-48. 10.1111/j.1651-2227.1996.tb13888.x.CrossRefPubMed
19.
go back to reference Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998, 21: 160-178. 10.2337/diacare.21.1.160.CrossRefPubMed Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998, 21: 160-178. 10.2337/diacare.21.1.160.CrossRefPubMed
20.
go back to reference Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003, 26 (Suppl 1): S83-S86.PubMed Haffner SM: Management of dyslipidemia in adults with diabetes. Diabetes Care. 2003, 26 (Suppl 1): S83-S86.PubMed
21.
go back to reference Zoppini G, Negri C, Stoico V, et al: Triglyceride–high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism. 2012, 61: 22-29. 10.1016/j.metabol.2011.05.004.CrossRefPubMed Zoppini G, Negri C, Stoico V, et al: Triglyceride–high-density lipoprotein cholesterol is associated with microvascular complications in type 2 diabetes mellitus. Metabolism. 2012, 61: 22-29. 10.1016/j.metabol.2011.05.004.CrossRefPubMed
22.
go back to reference Teramoto T, Shirai K, Daida H, Yamada N: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetology. 2012, 11: 29-10.1186/1475-2840-11-29.CrossRef Teramoto T, Shirai K, Daida H, Yamada N: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetology. 2012, 11: 29-10.1186/1475-2840-11-29.CrossRef
23.
go back to reference Grundy SM, Vega GL, Tomassini JE, Tershakovec AM: Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009, 104: 548-553. 10.1016/j.amjcard.2009.04.018.CrossRefPubMed Grundy SM, Vega GL, Tomassini JE, Tershakovec AM: Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). Am J Cardiol. 2009, 104: 548-553. 10.1016/j.amjcard.2009.04.018.CrossRefPubMed
24.
go back to reference Lu W, Resnick HE, Jablonski KA: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003, 26: 16-23. 10.2337/diacare.26.1.16.CrossRefPubMed Lu W, Resnick HE, Jablonski KA: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care. 2003, 26: 16-23. 10.2337/diacare.26.1.16.CrossRefPubMed
25.
go back to reference Querton L, Buysschaert M, Hermans MP, et al: Hypertriglyceridemia and residual dyslipidemia in statin-treatment patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol. Querton L, Buysschaert M, Hermans MP, et al: Hypertriglyceridemia and residual dyslipidemia in statin-treatment patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels. J Clin Lipidol.
26.
go back to reference Hermans MP, Ahn SA, Rousseau MF: log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes mellitus. Cardiovasc Diabetology. 2010, 9: 88-10.1186/1475-2840-9-88.CrossRef Hermans MP, Ahn SA, Rousseau MF: log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes mellitus. Cardiovasc Diabetology. 2010, 9: 88-10.1186/1475-2840-9-88.CrossRef
27.
go back to reference Keech A, Simes RJ, Barter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366: 1849-1861.CrossRefPubMed Keech A, Simes RJ, Barter P, et al: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366: 1849-1861.CrossRefPubMed
28.
go back to reference Keech AC, Mitchell P, Summanen PA, et al: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007, 370: 1687-1697. 10.1016/S0140-6736(07)61607-9.CrossRefPubMed Keech AC, Mitchell P, Summanen PA, et al: Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007, 370: 1687-1697. 10.1016/S0140-6736(07)61607-9.CrossRefPubMed
29.
go back to reference Toth PP: Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. Int J Clin Pract. 2009, 63: 903-911. 10.1111/j.1742-1241.2009.02053.x.CrossRefPubMed Toth PP: Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective. Int J Clin Pract. 2009, 63: 903-911. 10.1111/j.1742-1241.2009.02053.x.CrossRefPubMed
30.
go back to reference Chew EY, Ambrosius WT, Davis MD, et al: Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010, 363: 233-244.CrossRefPubMed Chew EY, Ambrosius WT, Davis MD, et al: Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010, 363: 233-244.CrossRefPubMed
31.
go back to reference Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005, 45: 485-493. 10.1053/j.ajkd.2004.11.004.CrossRefPubMed Ansquer JC, Foucher C, Rattier S, Taskinen MR, Steiner G: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis. 2005, 45: 485-493. 10.1053/j.ajkd.2004.11.004.CrossRefPubMed
Metadata
Title
The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
Authors
Peter P Toth
Robert J Simko
Swetha Rao Palli
Dawn Koselleck
Ralph A Quimbo
Mark J Cziraky
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-109

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue